PMID- 16541123
OWN - NLM
STAT- MEDLINE
DCOM- 20060623
LR  - 20121115
IS  - 1001-0602 (Print)
IS  - 1001-0602 (Linking)
VI  - 16
IP  - 3
DP  - 2006 Mar
TI  - Combinational adenovirus-mediated gene therapy and dendritic cell vaccine in 
      combating well-established tumors.
PG  - 241-59
AB  - Recent developments in tumor immunology and biotechnology have made cancer gene 
      therapy and immunotherapy feasible. The current efforts for cancer gene therapy 
      mainly focus on using immunogenes, chemogenes and tumor suppressor genes. Central 
      to all these therapies is the development of efficient vectors for gene therapy. 
      By far, adenovirus (AdV)-mediated gene therapy is one of the most promising 
      approaches, as has confirmed by studies relating to animal tumor models and 
      clinical trials. Dendritic cells (DCs) are highly efficient, specialized 
      antigen-presenting cells, and DC-based tumor vaccines are regarded as having much 
      potential in cancer immunotherapy. Vaccination with DCs pulsed with tumor 
      peptides, lysates, or RNA, or loaded with apoptotic/necrotic tumor cells, or 
      engineered to express certain cytokines or chemokines could induce significant 
      antitumor cytotoxic T lymphocyte (CTL) responses and antitumor immunity. Although 
      both AdV-mediated gene therapy and DC vaccine can both stimulate antitumor immune 
      responses, their therapeutic efficiency has been limited to generation of 
      prophylactic antitumor immunity against re-challenge with the parental tumor 
      cells or to growth inhibition of small tumors. However, this approach has been 
      unsuccessful in combating well-established tumors in animal models. Therefore, a 
      major strategic goal of current cancer immunotherapy has become the development 
      of novel therapeutic strategies that can combat well-established tumors, thus 
      resembling real clinical practice since a good proportion of cancer patients 
      generally present with significant disease. In this paper, we review the recent 
      progress in AdV-mediated cancer gene therapy and DC-based cancer vaccines, and 
      discuss combined immunotherapy including gene therapy and DC vaccines. We 
      underscore the fact that combined therapy may have some advantages in combating 
      well-established tumors vis-a-vis either modality administered as a monotherapy.
FAU - Xia, Dajing
AU  - Xia D
AD  - Research Unit, Health Research Division, Saskatchewan Cancer Agency, Department 
      of Oncology, University of Saskatchewan, 20 Campus Drive, Saskatoon, Saskatchewan 
      S7N 4H4, Canada.
FAU - Moyana, Terence
AU  - Moyana T
FAU - Xiang, Jim
AU  - Xiang J
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Cell Res
JT  - Cell research
JID - 9425763
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Cancer Vaccines)
RN  - 0 (Cytokines)
RN  - 0 (Prodrugs)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 147205-72-9 (CD40 Ligand)
RN  - EC 2.7.1.21 (Thymidine Kinase)
RN  - EC 3.5.4.1 (Cytosine Deaminase)
SB  - IM
MH  - Adenoviridae/*genetics
MH  - Animals
MH  - Antigens, Neoplasm/administration & dosage
MH  - Apoptosis/drug effects
MH  - CD40 Ligand/therapeutic use
MH  - Cancer Vaccines/*therapeutic use
MH  - Combined Modality Therapy/methods
MH  - Cytokines/administration & dosage
MH  - Cytosine Deaminase/administration & dosage
MH  - Dendritic Cells/*immunology
MH  - Genes, Tumor Suppressor
MH  - *Genetic Therapy/adverse effects
MH  - Humans
MH  - Neoplasms/immunology/*therapy
MH  - Prodrugs/metabolism
MH  - T-Lymphocytes, Cytotoxic/immunology
MH  - Thymidine Kinase/administration & dosage
MH  - Tumor Necrosis Factor-alpha/therapeutic use
RF  - 169
EDAT- 2006/03/17 09:00
MHDA- 2006/06/24 09:00
CRDT- 2006/03/17 09:00
PHST- 2006/03/17 09:00 [pubmed]
PHST- 2006/06/24 09:00 [medline]
PHST- 2006/03/17 09:00 [entrez]
AID - 7310032 [pii]
AID - 10.1038/sj.cr.7310032 [doi]
PST - ppublish
SO  - Cell Res. 2006 Mar;16(3):241-59. doi: 10.1038/sj.cr.7310032.